Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry André

Showing results (1-10 of 309) with videos related to

Pageof 31
Sort By:
Bulletin Du Cancer|February 4, 2019
[Microsatellite instability (MSI): best predictor of effectiveness of immune checkpoint inhibitors (ICKi)? Focus on MSI by Bulletin du Cancer]Thierry André
The Lancet Regional Health. Europe|September 24, 2021
Centralized multidisciplinary team assessment of metastasis resectability in patients with metastatic colorectal cancer: A fundamental necessityThierry André
Bulletin Du Cancer|May 14, 2021
[Is high tumor mutation burden predictive of immune checkpoint blockade efficacy in terms of overall survival across all cancer types?]Thierry André, Romain Cohen
Bulletin Du Cancer|May 20, 2018
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]Thierry André, Julien Taieb,
The Lancet. Gastroenterology & Hepatology|October 24, 2021
Immune checkpoint inhibitors in colorectal cancer: dream and realityThierry André, Romain Cohen
Bulletin Du Cancer|September 20, 2013
[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]Thierry André, Benoist Chibaudel
Bulletin Du Cancer|June 30, 2015
[Is it necessary to perform a surgery after neo-adjuvant treatment for initially borderline or locally advanced pancreatic adenocarcinoma?]Thierry André, François Paye
JCO Oncology Practice|April 3, 2023
Designing Trials for Neoadjuvant Immune Checkpoint Inhibition in Microsatellite Instability-High Localized Colorectal CancerThierry André, Romain Cohen
Bulletin Du Cancer|July 9, 2004
[Cyclo-oxygenase 2 inhibitors and cancer]Thierry André, Jean-Charles Soria
Bulletin Du Cancer|February 24, 2006
[A good cooperation between industry and French medical oncologists]Thierry André, Aimery De Gramont
Pageof 31

Showing results (1-10 of 309) with videos related to

Sort By:
Pageof 31
Bulletin Du Cancer|February 4, 2019
[Microsatellite instability (MSI): best predictor of effectiveness of immune checkpoint inhibitors (ICKi)? Focus on MSI by Bulletin du Cancer]Thierry André
The Lancet Regional Health. Europe|September 24, 2021
Centralized multidisciplinary team assessment of metastasis resectability in patients with metastatic colorectal cancer: A fundamental necessityThierry André
Bulletin Du Cancer|May 14, 2021
[Is high tumor mutation burden predictive of immune checkpoint blockade efficacy in terms of overall survival across all cancer types?]Thierry André, Romain Cohen
Bulletin Du Cancer|May 20, 2018
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]Thierry André, Julien Taieb,
The Lancet. Gastroenterology & Hepatology|October 24, 2021
Immune checkpoint inhibitors in colorectal cancer: dream and realityThierry André, Romain Cohen
Bulletin Du Cancer|September 20, 2013
[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]Thierry André, Benoist Chibaudel
Bulletin Du Cancer|June 30, 2015
[Is it necessary to perform a surgery after neo-adjuvant treatment for initially borderline or locally advanced pancreatic adenocarcinoma?]Thierry André, François Paye
JCO Oncology Practice|April 3, 2023
Designing Trials for Neoadjuvant Immune Checkpoint Inhibition in Microsatellite Instability-High Localized Colorectal CancerThierry André, Romain Cohen
Bulletin Du Cancer|July 9, 2004
[Cyclo-oxygenase 2 inhibitors and cancer]Thierry André, Jean-Charles Soria
Bulletin Du Cancer|February 24, 2006
[A good cooperation between industry and French medical oncologists]Thierry André, Aimery De Gramont
Pageof 31